Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI...

Area of Science:

• Immunology
• Neuroscience

Background:

• Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Interferon-beta (IFN-β) is a common treatment for relapsing-remitting MS (RRMS).
• Cytokine profiles may predict treatment response and disease activity in MS patients.

Purpose of the Study:

• To compare serum and cellular cytokine changes in RRMS patients treated with different IFN-β-1a regimens.
• To investigate the relationship between cytokine profiles and treatment response based on MRI criteria.

Main Methods:

• 15 RRMS patients received either once-weekly intramuscular or three-times-weekly subcutaneous IFN-β-1a for 24 weeks.
• Serum and peripheral blood mononuclear cell (PBMC) cytokine levels (IL-10, IL-12p40, IL-12p70, IFN-gamma) were measured.
• Patients were categorized as responders or non-responders based on MRI-defined disease activity.

Main Results:

• IFN-β treatment increased cellular IL-10 and IL-10/IL-12 ratios, while decreasing cellular IFN-gamma.
• Non-responders exhibited decreased serum IL-10 levels and reduced serum IL-10/IL-12p70 ratios.
• Non-responders also showed a decrease in cellular IL-12p70, whereas responders had decreased cellular IFN-gamma.

Conclusions:

• IFN-β therapy alters cytokine profiles in MS patients.
• Decreased serum IL-10 levels in non-responders correlate with persistent MRI-defined disease activity.
• This study provides insights into differential cytokine responses to IFN-β treatment in MS.